TITLE

The Use of Aspirin for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force

AUTHOR(S)
Dubé, Catherine; Rostom, Alaa; Lewin, Gabriela; Tsertsvadze, Alexander; Barrowman, Nicholas; Code, Catherine; Sampson, Margaret; Moher, David
PUB. DATE
March 2007
SOURCE
Annals of Internal Medicine;3/6/2007, Vol. 146 Issue 5, p365
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Aspirin for prevention of colorectal cancer is controversial. Purpose: To examine the benefits and harms of aspirin chemoprevention. Data Sources: MEDLINE, 1966 to December 2006; EMBASE, 1980 to April 2005; CENTRAL, Cochrane Collaboration's registry of clinical trials; Cochrane Database of Systematic Reviews. Study Selection: Two independent reviewers conducted multilevel screening to identify randomized, controlled trials (RCTs), case-control studies, and cohort studies of aspirin chemoprophylaxis. For harms, systematic reviews were sought. Data Extraction: In duplicate, data were abstracted and checked and quality was assessed. Data Synthesis: Regular use of aspirin reduced the incidence of colonic adenomas in RCTs (relative risk [RR], 0.82 [95% CI, 0.7 to 0.95]), case-control studies (RR, 0.87 [CI, 0.77 to 0.98]), and cohort studies (RR, 0.72 [CI, 0.61 to 0.85]). In cohort studies, regular use of aspirin was associated with RR reductions of 22% for incidence of colorectal cancer. Two RCTs of low-dose aspirin failed to show a protective effect. Data for colorectal cancer mortality were limited. Benefits from chemoprevention were more evident when aspirin was used at a high dose and for periods longer than 10 years. Aspirin use was associated with a dose-related increase in incidence of gastrointestinal complications. Limitations: Important clinical and methodological heterogeneity in the definitions of regular use, dose, and duration of use of aspirin necessitated careful grouping for analysis. Conclusions: Aspirin appears to be effective at reducing the incidence of colonic adenoma and colorectal cancer, especially if used in high doses for more than 10 years. However, the possible harms of such a practice require careful consideration. Further evaluation of the cost-effectiveness of chemoprevention compared with, and in combination with, a screening strategy is required.
ACCESSION #
24334085

 

Related Articles

  • Aspirin or Nonsteroidal Anti-inflammatory Drugs for the Prevention of Colorectal Cancer: U.S. Preventive Services Task Force Recommendations.  // Annals of Internal Medicine;3/6/2007, Vol. 146 Issue 5, pI35 

    The article offers information concerning the use of aspirin of non-steroidal anti-inflammatory drugs for the prevention of colorectal cancer. A brief description of colorectal cancer is provided, including the ways of preventing the disease such as the chemoprevention and taking doses of...

  • Routine Aspirin or Nonsteroidal Anti-inflammatory Drugs for the Primary Prevention of Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.  // Annals of Internal Medicine;3/6/2007, Vol. 146 Issue 5, p361 

    This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendation and supporting scientific evidence on routine use of aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer. The complete information on which this statement is...

  • Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force. Rostom, Alaa; Dubeé, Catherine; Lewin, Gabriela; Tsertsvadze, Alexander; Barrowman, Nicholas; Code, Catherine; Sampson, Margaret; Moher, David // Annals of Internal Medicine;3/6/2007, Vol. 146 Issue 5, p376 

    Purpose: To examine the benefits and harms of nonaspirin (non-ASA) nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase (COX-2) inhibitors for the prevention of colorectal cancer (CRC) and adenoma. Data Sources: MEDLINE (1966 to 2006), EMBASE (1980 to 2006), Cochrane Central Register...

  • Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells. Strillacci, A.; Griffoni, C.; Lazzarini, G.; Valerii, M. C.; Di Molfetta, S.; Rizzello, F.; Campieri, M.; Moyer, M. P.; Tomasi, V.; Spisni, E. // British Journal of Cancer;9/28/2010, Vol. 103 Issue 7, p975 

    Background:Cyclooxygenase-2 (COX-2) overexpression is strongly associated with colorectal tumourigenesis. It has been demonstrated that the chronic use of non-steroidal anti-inflammatory drugs (COX inhibitors) partially protects patients from colorectal cancer (CRC) development and progression...

  • Aspirin protects men over 60 from prostate cancer, study says. Gottlieb, Scott // BMJ: British Medical Journal (International Edition);3/23/2002, Vol. 324 Issue 7339, p696 

    Reports that regular use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) may protect against the development of prostate cancer in older men according to a study published in 'Mayo Clinic Proceedings.' Details of the study; Percentage of men taking the drugs who developed...

  • NSAID use modified link between COX2, colorectal cancer risk. Adams, Stacey L.; Harris, Jason; Lawrence, Leah // Hem/Onc Today;5/25/2009, Vol. 10 Issue 10, p24 

    The article deals with a study on the role of nonsteroidal antiinflammatory drugs in altering the link between COX2 and colorectal cancer risk, presented by Anna E. Coghill and colleagues at the annual meeting of the American Association for Cancer Research held in Denver, Colorado from April 18...

  • Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs. Fink, Stephen P.; Dawson, Dawn M.; Zhang, Yongyou; Kresak, Adam; Lawrence, Earl G.; Yang, Peiying; Chen, Yanwen; Barnholtz-Sloan, Jill S.; Willis, Joseph E.; Kopelovich, Levy; Markowitz, Sanford D. // Carcinogenesis;Feb2015, Vol. 36 Issue 2, p291 

    Non-steroidal anti-inflammatory drugs prevent colorectal cancer by inhibiting cyclooxygenase (COX) enzymes that synthesize tumor-promoting prostaglandins. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is a tumor suppressor that degrades tumor-promoting prostaglandins. Murine knockout of...

  • Risk breaker? Munson, Marty; Higbee, Beth // Prevention;Jul96, Vol. 48 Issue 7, p19 

    Cites a report published in the March 1996 issue of `Epidemiology' periodical stating that aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) can prevent risks of breast cancer in women. List of NSAIDs that may be used to prevent the disease; Study leader Randall Harris'...

  • Genetic and lifestyle influence on telomere length and subsequent risk of colon cancer in a case control study. Pellatt, Andrew J.; Wolff, Roger K.; Lundgreen, Abbie; Cawthon, Richard; Slattery, Martha L. // International Journal of Molecular Epidemiology & Genetics;2012, Vol. 3 Issue 3, p184 

    Background: Telomeres cap the ends of chromosomes and help maintain genomic stability and integrity. Telomere length (TL) has been linked to a number of diseases, including a variety of cancers; however, the association between TL and risk for colorectal cancer is unclear. Methods: We...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics